BioRegenx Reports 39% Decline in Q2 2025 Net Sales, Seeks Additional Financing

BioRegenx, Inc. reported a significant decline in financial performance for the second quarter of 2025, with net sales of $445,970, a 39% decrease from $734,032 in the same period of 2024. Gross sales also fell by 48% to $446,784, down from $857,534. The company attributed this decline primarily to product issues with its medical testing machines, which negatively impacted sales across its product lines. Despite the drop in revenue, the cost of sales decreased by 65% to $93,514, resulting in a gross profit of $352,456, down 25% from the previous year.

In terms of operating expenses, BioRegenx reported a total of $459,715 for the quarter, a substantial reduction of 70% compared to $1,509,675 in the prior year. This decrease was largely due to a significant reduction in selling, general, and administrative expenses, which fell from $1,397,087 to $456,728. The company recorded a loss from operations of $107,259, a notable improvement from the loss of $1,039,797 reported in the same quarter of 2024. The net loss for the quarter was $178,345, an 84% reduction from the previous year's loss of $1,106,128.

For the first half of 2025, BioRegenx's net sales totaled $961,116, down 25% from $1,283,580 in the first half of 2024. Gross sales for this period were $963,274, a decrease of 38% year-over-year. The company reported a net loss of $445,199 for the six months ended June 30, 2025, compared to a loss of $4,258,586 in the same period of 2024, reflecting a 90% improvement. The reduction in losses was attributed to lower operating expenses and improved cash management.

Strategically, BioRegenx has been focusing on consolidating its operations following the acquisition of DocSun Biomedical Holdings, Inc. in January 2024. The company is also navigating challenges related to its product lines and market conditions, which have affected its distributor base. As of June 30, 2025, the company had a stockholders' deficit of $3,654,708 and cash reserves of $46,456, raising concerns about its ability to continue as a going concern. The company has indicated that it will need to secure additional financing to support ongoing operations and development efforts.

Looking ahead, BioRegenx's management has expressed the need for substantial capital to fund working capital and pursue business development plans. The company is exploring options for raising funds through debt or equity financing, although there is no assurance that such financing will be available or on favorable terms. The ongoing challenges with product performance and market conditions will likely continue to impact the company's financial outlook in the near term.